Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. [electronic resource]
Producer: 20170124Description: 3418-31 p. digitalISSN:- 2219-2840
- Adolescent
- Adult
- Aged
- Antiviral Agents -- adverse effects
- Carbamates
- Drug Resistance, Viral -- genetics
- Drug Therapy, Combination
- Female
- Genotype
- Hepacivirus -- drug effects
- Hepatitis C, Chronic -- diagnosis
- Humans
- Imidazoles -- adverse effects
- Interferon-alpha -- adverse effects
- Interferons
- Interleukins -- genetics
- Male
- Middle Aged
- Oligopeptides -- adverse effects
- Polyethylene Glycols -- adverse effects
- Polymorphism, Genetic
- Pyrrolidines
- RNA, Viral -- blood
- Recombinant Proteins -- adverse effects
- Ribavirin -- adverse effects
- Time Factors
- Treatment Outcome
- Valine -- analogs & derivatives
- Viral Load
- Viral Nonstructural Proteins -- antagonists & inhibitors
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.